CRO concept stocks are leading the advances in Hong Kong trading, with Asymchem (06821) jumping 5.89% to HK$142.10, Pharmaron (03759) climbing 4.72% to HK$28.84, TigerMed (03347) rising 4.64% to HK$43.32, and Wuxi Bio (02269) adding 2.30% to HK$48.08 as of the latest update.

On the news front, interim results from both domestic and international CXO companies continue to validate the sector's strong growth trajectory. According to Sinolink Securities, recent overseas CXO firms have released their 2026 interim reports, revealing notable improvements in second-quarter orders across the board, with particularly strong gains in preclinical book-to-bill metrics. Most companies have also revised their earnings guidance upward.

Domestically, WuXi AppTec's interim report significantly exceeded market expectations, prompting the company to raise its full-year guidance substantially. Goldman Sachs highlighted in a research note that second-quarter and first-half results reflect a clear recovery in China's CRO/CDMO industry, with earnings surpassing projections, upward guidance revisions, and robust order momentum. The investment bank expressed a favorable outlook on the WuXi group, Pharmaron, Asymchem, TigerMed, and GenScript.